Research Analysts Set Expectations for ACRV Q1 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Stock analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for shares of Acrivon Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.53) per share for the quarter, up from their prior estimate of ($0.54). HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.38) EPS, FY2027 earnings at ($1.67) EPS, FY2028 earnings at ($1.11) EPS, FY2029 earnings at ($0.84) EPS and FY2030 earnings at $0.04 EPS.

Several other analysts also recently issued reports on the company. Jefferies Financial Group restated a “buy” rating on shares of Acrivon Therapeutics in a report on Monday, March 2nd. Wall Street Zen cut shares of Acrivon Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 1st. Piper Sandler lifted their target price on shares of Acrivon Therapeutics from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Acrivon Therapeutics in a report on Monday, December 29th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Acrivon Therapeutics has an average rating of “Moderate Buy” and an average target price of $11.67.

Acrivon Therapeutics Stock Down 2.4%

Shares of NASDAQ ACRV opened at $1.66 on Monday. Acrivon Therapeutics has a 12 month low of $1.05 and a 12 month high of $5.65. The company has a market cap of $64.31 million, a price-to-earnings ratio of -0.82 and a beta of 1.79. The business has a fifty day simple moving average of $1.71 and a 200-day simple moving average of $1.95.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its earnings results on Thursday, March 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.49).

Insider Transactions at Acrivon Therapeutics

In other Acrivon Therapeutics news, CEO Peter Blume-Jensen acquired 49,000 shares of Acrivon Therapeutics stock in a transaction that occurred on Wednesday, January 14th. The stock was purchased at an average cost of $1.68 per share, with a total value of $82,320.00. Following the purchase, the chief executive officer owned 2,095,771 shares in the company, valued at approximately $3,520,895.28. The trade was a 2.39% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders bought 67,832 shares of company stock valued at $114,534. 8.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Acrivon Therapeutics

Large investors have recently made changes to their positions in the business. UBS Group AG boosted its holdings in shares of Acrivon Therapeutics by 150,057.8% during the third quarter. UBS Group AG now owns 683,218 shares of the company’s stock worth $1,237,000 after purchasing an additional 682,763 shares during the period. Marshall Wace LLP increased its stake in Acrivon Therapeutics by 231.4% in the 4th quarter. Marshall Wace LLP now owns 496,081 shares of the company’s stock valued at $1,196,000 after buying an additional 346,366 shares during the period. Jane Street Group LLC purchased a new stake in Acrivon Therapeutics in the 2nd quarter worth approximately $371,000. Two Sigma Investments LP lifted its position in Acrivon Therapeutics by 76.2% in the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock worth $578,000 after buying an additional 138,033 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Acrivon Therapeutics during the 2nd quarter valued at $126,000. Institutional investors and hedge funds own 71.62% of the company’s stock.

More Acrivon Therapeutics News

Here are the key news stories impacting Acrivon Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple quarterly and annual EPS estimates (Q1–Q4 2026, FY2026–FY2030), narrowing projected losses and moving FY2030 to a small positive EPS; the firm reiterated a “Buy” rating and a $19 price target. HC Wainwright note
• Neutral Sentiment: The EPS upgrades are incremental (small changes in cents per quarter/year) — they improve the trajectory but do not materially change near-term cash-burn or clinical-development risk; consensus for FY2026 remains a sizeable loss.
• Negative Sentiment: Shares are trading down today amid low liquidity (volume below the three‑month average), below both the 50‑day and 200‑day moving averages, and following recent quarterly results that showed continued losses — all factors that can trigger short‑term selling/pressure in a small‑cap biotech with a high beta.

About Acrivon Therapeutics

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.